Spironolactone and Hydrochlorothiazide
Spironolactone and Hydrochlorothiazide is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Spironolactone and Hydrochlorothiazide; Generic name: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE; Drug class: Thiazide Diuretic [EPC].
| Brand name | Spironolactone and Hydrochlorothiazide |
|---|---|
| Generic name | SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE |
| Drug class | Thiazide Diuretic [EPC] |
| Manufacturer | Mylan Pharmaceuticals Inc. |
| Used for | INDICATIONS AND USAGE Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see Precautions section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and hydrochlorothiazide tablets are indicated for: Edematous conditions for patients with: Congestive heart failure: • For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; • The treatment of diuretic-induced hypokalemia in patients with co |
| Dosage | DOSAGE AND ADMINISTRATION Optimal dosage should be established by individual titration of the components. Edema in adults ( congestive heart failure, hepatic cirrhosis, or nephrotic syndrome) The usual maintenance dose of spironolactone and hydrochlorothiazide tablets is 100 mg each of spironolactone and hydrochlorothiazide daily, administered in a single dose or in divided doses, but may range from 25 mg to 200 mg of each component daily depending on the response to the initial titration. In so |
| Warnings | WARNINGS Potassium supplementation, either in the form of medication or as a diet rich in potassium, should not ordinarily be given in association with spironolactone and hydrochlorothiazide therapy. Excessive potassium intake may cause hyperkalemia in patients receiving spironolactone and hydrochlorothiazide (see Precautions: General ). Concomitant administration of spironolactone and hydrochlorothiazide with the following drugs or potassium sources may lead to severe hyperkalemia: • other pota |
| Active ingredient(s) | HYDROCHLOROTHIAZIDE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c8c973f-13a2-4883-8316-4006398e2931 |